by Raynovich Rod | Jun 16, 2017 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Rayno Life Science Portfolio
Update-1 6/27/17 With the XBI up 34% YTD at $79.34, take a little off for future trades. ===== Rayno Life Science Portfolio 2017 YTD 6/15 Top winners YTD: BLUE up 78.9%,FMI up 121.5%,RHHBY up 13%, ABBV up 12.7%. Top Losers YTD: GILD down 9.5%, BMY down 7%. XBI up...
by Raynovich Rod | Apr 25, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update #2 Large Cap Biopharmaceuticals: ABBV, ALXN, BMY, CELG Abbvie (ABBV) Reported Better than Expected Earnings and Revenues Worldwide GAAP revenues were $6.538B up 10.1% with Global Humira sales up 15.1% and Q1 IMBRUVICA sales of $551M. Full Year 2017 outlook for...
by Raynovich Rod | Mar 29, 2017 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update…3/31/17 Performance %: March and YTD FBT -0.83, +15.87 FBIOX -2.43, +15.79 * Fidelity ahead of IBB in 2017 IBB -3.05,+10.5 QQQ +1.04, +11.73 XBI -2.82, +17.15 XLV -1.9, +7.86 Notable Rayno Portfolio Picks %: March and YTD ABBV +2.9, +4.08 AMGN...
by Raynovich Rod | Feb 20, 2017 | 2025 Rayno Biopharmaceuticals Portfolio
Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79....
by Raynovich Rod | Nov 16, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Trump Biotech Rally-Have a Balanced Portfolio Everybody who invests in biotech knows there has been a Trump biotech rally since his election as you can see from the chart and data below. Many opinions and analysis were given for the rally.Some pundits say it is...
by Raynovich Rod | Sep 29, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… See Caution 9/29 Update-2…See Rayno Biobeat for updates after Trump Rally. For overweighting biotechs in a portfolio consider XBI instead of IBB to get mid and small cap exposure. ——– Rayno Portfolio Outperforms the Market...
by Raynovich Rod | Sep 12, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 9/13… Hard to Call Next Move: Macro and i Rates Rule The market was rattled at the opening with the IEA news on cuts in the demand forecast for crude which dropped 2.33%. Subsequently FED hike fears returned causing more volatility with stocks...
by Raynovich Rod | Jul 21, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… Gilead Sciences (GILD) Sells Off on earnings Gilead Sciences (GILD) sold off over 4% after hours after releasing second quarter sales of $7.7B and earnings of $3.08/sh. Q2 profit forecast beat. The full year revenue forecast was also cut slightly by...
by Raynovich Rod | Jul 11, 2016 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1… 7/12/16 Dow and S&P Hit Record Highs, Awaiting Q2 Earnings-Risk Still On-Biotech Stocks Lag The market continued its post-BREXIT rally helped by low interest rates and WTI crude up 4.56% to $46.80. Gold eased off and the dollar was up. We are still...
by Raynovich Rod | Jul 5, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Foundation Medicine (FMI) New Pick at $20.40 We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make...
